Mike Dawson Antimicrobial Research Consultancy Limited 10924881 false 2022-09-01 2023-08-31 2023-08-31 The principal activity of the company is Provision of consultancy services in pharmaceutical research and development, microbiology and biochemistry Digita Accounts Production Advanced 6.30.9574.0 true false 10924881 2022-09-01 2023-08-31 10924881 2023-08-31 10924881 bus:OrdinaryShareClass1 2023-08-31 10924881 core:CurrentFinancialInstruments 2023-08-31 10924881 core:CurrentFinancialInstruments core:WithinOneYear 2023-08-31 10924881 core:FurnitureFittingsToolsEquipment 2023-08-31 10924881 bus:SmallEntities 2022-09-01 2023-08-31 10924881 bus:AuditExemptWithAccountantsReport 2022-09-01 2023-08-31 10924881 bus:FullAccounts 2022-09-01 2023-08-31 10924881 bus:SmallCompaniesRegimeForAccounts 2022-09-01 2023-08-31 10924881 bus:RegisteredOffice 2022-09-01 2023-08-31 10924881 bus:Director1 2022-09-01 2023-08-31 10924881 bus:OrdinaryShareClass1 2022-09-01 2023-08-31 10924881 bus:PrivateLimitedCompanyLtd 2022-09-01 2023-08-31 10924881 core:FurnitureFittingsToolsEquipment 2022-09-01 2023-08-31 10924881 core:OfficeEquipment 2022-09-01 2023-08-31 10924881 1 2022-09-01 2023-08-31 10924881 countries:UnitedKingdom 2022-09-01 2023-08-31 10924881 2022-08-31 10924881 core:FurnitureFittingsToolsEquipment 2022-08-31 10924881 2021-09-01 2022-08-31 10924881 2022-08-31 10924881 bus:OrdinaryShareClass1 2022-08-31 10924881 core:CurrentFinancialInstruments 2022-08-31 10924881 core:CurrentFinancialInstruments core:WithinOneYear 2022-08-31 10924881 core:FurnitureFittingsToolsEquipment 2022-08-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10924881

Mike Dawson Antimicrobial Research Consultancy Limited

Unaudited Financial Statements

for the Year Ended 31 August 2023

 

Mike Dawson Antimicrobial Research Consultancy Limited

Contents

Balance Sheet

1

Notes to the Unaudited Financial Statements

2 to 6

 

Mike Dawson Antimicrobial Research Consultancy Limited

(Registration number: 10924881)
Balance Sheet as at 31 August 2023

Note

2023
£

2022
£

Fixed assets

 

Tangible assets

4

999

1,374

Current assets

 

Debtors

5

4,690

4,685

Cash at bank and in hand

 

42,674

24,125

 

47,364

28,810

Creditors: Amounts falling due within one year

6

(10,122)

(7,602)

Net current assets

 

37,242

21,208

Total assets less current liabilities

 

38,241

22,582

Provisions for liabilities

(190)

(261)

Net assets

 

38,051

22,321

Capital and reserves

 

Called up share capital

100

100

Retained earnings

37,951

22,221

Shareholders' funds

 

38,051

22,321

For the financial year ending 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 6 November 2023
 

.........................................
Mr Michael Dawson
Director

 

Mike Dawson Antimicrobial Research Consultancy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2023

1

General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:
Unit 1, The Cam Centre
Wilbury Way
Hitchin
Hertfordshire
SG4 0TW

The principal place of business is:
33A High Street
Pirton
Hitchin
Hertfordshire
SG5 3PS

These financial statements were authorised for issue by the director on 6 November 2023.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the entity.

 

Mike Dawson Antimicrobial Research Consultancy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2023

Judgements

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

25% Straight Line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits.

 

Mike Dawson Antimicrobial Research Consultancy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2023

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2022 - 1).

 

Mike Dawson Antimicrobial Research Consultancy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2023

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 September 2022

2,549

2,549

At 31 August 2023

2,549

2,549

Depreciation

At 1 September 2022

1,175

1,175

Charge for the year

375

375

At 31 August 2023

1,550

1,550

Carrying amount

At 31 August 2023

999

999

At 31 August 2022

1,374

1,374

5

Debtors

Current

2023
£

2022
£

Prepayments

4,690

4,685

6

Creditors

Creditors: amounts falling due within one year

2023
£

2022
£

Due within one year

Taxation and social security

8,687

7,528

Accruals and deferred income

1,188

-

Other creditors

247

74

10,122

7,602




 

 

Mike Dawson Antimicrobial Research Consultancy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2023

7

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

£

No.

£

Ordinary Share Capital of £1 each

100

100

100

100

         

8

Dividends

   

2023

 

2022

   

£

 

£

Final dividend of £210.00 (2022 - £290.00) per ordinary share

 

21,000

 

29,000

         

9

Related party transactions

At the balance sheet date, the company owed £248 (2022: £74) to Michael Dawson. There are no terms relating to the payment of interest or repayment of capital on this loan.

10

Ultimate controlling party

The ultimate controlling party is Michael Dawson by virtue of his majority shareholding.